I see this as a much more positive step than the previous news, moving towards participating in drug manufacturing technology rather than selling enzymes for others to research. So, two different lines are being built: Research tools and Therapeutics licensing.
This new move has a really big upside. One could even call it exponential. BUT: there are no royalties, so it wouldn’t get Kevin O’Leary excited. I’m eagerly awaiting the first milestone payments.
6 Likes